Citi initiated coverage of Gilead (GILD) with a Buy rating and $125 price target The firm says that despite the stock’s near-term ...

Sciences presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial, which is studying ...

Gilead (GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir ...

Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE ...

Gilead Sciences has announced new data from its pivotal Phase III PURPOSE 2 trial providing further details on the efficacy, ...

He expressed optimism that this growth will continue, driven by the potential approval of lenacapavir as a preventive ...

What is patent evergreening and what does the Indian patent regime tell us about it? Also, go beyond the nugget to know about ...

The results from the PURPOSE 2 study, which build on the 100% efficacy shown in PURPOSE 1, demonstrate lenacapavir's unmatched clinical profile observed for HIV prevention. If approved, lenacapavir, ...

City-level hospitals purchase 14 large medical appliances, all from leading international companies, at the CIIE on Friday alongside cooperation on infectious disease management.

Revolutionary new HIV drugs are being made available in 120 low-income countries, but many important populations are being left out. Sophie Cousins reports.

We need nothing less than disruptive action to ensure everyone who wants access to affordable lenacapavir can get it.

Gilead Sciences posted robust revenue and EPS growth, exceeding expectations, and management raised full-year guidance.